Incidence of brain metastasis and outcomes in patients with RET-rearranged lung cancers treated with multi-kinase inhibitor therapy

Trial Profile

Incidence of brain metastasis and outcomes in patients with RET-rearranged lung cancers treated with multi-kinase inhibitor therapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Alectinib (Primary) ; Cabozantinib (Primary) ; Lenvatinib (Primary) ; Ponatinib (Primary) ; Vandetanib (Primary)
  • Indications Lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Jun 2017 Results assessing baseline brain metastasis and outcomes with multikinase inhibitor therapy in patients with RET-rearranged lung cancers from a global registry and a phase II trial (NCT01639508), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top